Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy shows promise for Hard-to-Treat lung cancer

NCT ID NCT06525246

Completed Disease control Sponsor: Ono Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a new drug called ONO-7475 combined with the standard targeted therapy osimertinib in 78 people with advanced EGFR-mutated non-small cell lung cancer. The goal was to see if the combination is safe and tolerable. Participants had stage IIIB, IIIC, IV, or recurrent lung cancer not suitable for radiation. The study measured side effects, drug levels in the body, and how well the cancer responded.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EGFR MUTATION-RELATED TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EGFR MUTATION-RELATED TUMORS RECURRENT NON-SMALL CELL LUNG CANCER STAGE IIIB NON-SMALL CELL LUNG CANCER STAGE IIIC NON-SMALL CELL LUNG CANCER STAGE IV NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

  • Hyogo College Of Medicine College Hospital

    Nishinomiya, Hyōgo, Japan

  • Kanagawa Cancer Center

    Yokohama, Kanagawa, Japan

  • Kitasato University Hospital

    Sagamihara-shi, Kanagawa, Japan

  • Kobe City Medical Center General Hospital

    Kobe, Hyōgo, Japan

  • National Hospital Organization Shikoku Cancer Center

    Matsuyama, Ehime, Japan

  • Nigata Cancer Center Hospital

    Niigata, Niigata, Japan

  • Osaka International Cancer Institute

    Osaka, Osaka, Japan

  • Osaka Medical and Pharmaceutical University Hospital

    Takatsuki, Osaka, Japan

  • Saitama Cancer Center

    Ina, Kitaadati-gun, Saitama, Japan

  • Shizuoka Cancer Center

    Nagaizumi-chō, Sunto-gun, Shizuoka, Japan

  • The Cancer Institute Hospital Of JFCR

    Koto-Ku, Tokyo, Japan

  • Tokyo Medical University Hospital

    Shinjuku-Ku, Tokyo, Japan

  • University Hospital Kyoto Prefectural University of Medicine

    Kyoto, Kyoto, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.